Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
J Hosp Infect ; 105(4): 757-765, 2020 Aug.
Article de Anglais | MEDLINE | ID: mdl-32565368

RÉSUMÉ

BACKGROUND: Carbapenem non-susceptible Enterobacterales (CNSE) can be broadly divided into those that produce carbapenemases (carbapenemase-producing Enterobacterales (CPE)), and those that harbour other mechanisms of resistance (non-carbapenemase-producing CNSE (NCP-CNSE)). AIM: To determine the predictors of CNSE nosocomial incidence rates according to their mechanism of resistance. METHODS: A time-series analysis was conducted (July 2013 to December 2018) to evaluate the relationship in time between hospital antibiotic use and the percentage of adherence to hand hygiene with the CNSE rates. FINDINGS: In all, 20,641 non-duplicated Enterobacterales isolates were identified; 2.2% were CNSE. Of these, 48.1% and 51.9% were CPE and NCP-CNSE, respectively. Of the CPE, 78.3% possessed a blaOXA-232 gene. A transfer function model was identified for CNSE, CPE, and OXA-232 CPE that explained 20.8%, 19.3%, and 24.2% of their variation, respectively. According to the CNSE and CPE models, an increase in piperacillin-tazobactam (TZP) use of 1 defined daily dose (DDD) per 100 hospital patient-days (HPD) would lead to an increase of 0.69 and 0.49 CNSE and CPE cases per 10,000 HPD, respectively. The OXA-232 CPE model estimates that an increase of 1 DDD per 100 HPD of TZP use would lead to an increase of 0.43 OXA-232 CPE cases per 10,000 HPD. A transfer function model was not identified for NCP-CNSE, nor was there an association between the adherence to handhygiene and the CNSE rates. CONCLUSION: The use of TZP is related in time with the CPE nosocomial rates, mostly explained by its effect on OXA-232 CPE.


Sujet(s)
Antibactériens/pharmacologie , Enterobacteriaceae résistantes aux carbapénèmes/effets des médicaments et des substances chimiques , Carbapénèmes/pharmacologie , Résistance bactérienne aux médicaments , Infections à Enterobacteriaceae/traitement médicamenteux , Antibactériens/usage thérapeutique , Protéines bactériennes/génétique , Enterobacteriaceae résistantes aux carbapénèmes/enzymologie , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Utilisation médicament , Hôpitaux , Humains , Incidence , Tests de sensibilité microbienne , Facteurs temps , bêta-Lactamases/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE